DK3129018T3 - Behandling af NAFLD og NASH - Google Patents
Behandling af NAFLD og NASH Download PDFInfo
- Publication number
- DK3129018T3 DK3129018T3 DK15728222.9T DK15728222T DK3129018T3 DK 3129018 T3 DK3129018 T3 DK 3129018T3 DK 15728222 T DK15728222 T DK 15728222T DK 3129018 T3 DK3129018 T3 DK 3129018T3
- Authority
- DK
- Denmark
- Prior art keywords
- nafld
- nash
- treatment
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461978335P | 2014-04-11 | 2014-04-11 | |
| PCT/US2015/025416 WO2015157697A1 (en) | 2014-04-11 | 2015-04-10 | Treatment of nafld and nash |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3129018T3 true DK3129018T3 (da) | 2020-01-20 |
Family
ID=53373532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15728222.9T DK3129018T3 (da) | 2014-04-11 | 2015-04-10 | Behandling af NAFLD og NASH |
Country Status (26)
| Country | Link |
|---|---|
| US (7) | US9381181B2 (da) |
| EP (1) | EP3129018B1 (da) |
| JP (1) | JP6865038B2 (da) |
| KR (1) | KR102374499B1 (da) |
| CN (1) | CN106163508A (da) |
| AU (1) | AU2015243239B2 (da) |
| BR (1) | BR112016023269A8 (da) |
| CA (1) | CA2944139C (da) |
| CL (1) | CL2016002517A1 (da) |
| CY (1) | CY1122602T1 (da) |
| DK (1) | DK3129018T3 (da) |
| EA (1) | EA036704B1 (da) |
| ES (1) | ES2764467T3 (da) |
| HR (1) | HRP20192299T1 (da) |
| IL (1) | IL248193B (da) |
| LT (1) | LT3129018T (da) |
| MX (1) | MX369921B (da) |
| NZ (1) | NZ724740A (da) |
| PH (1) | PH12016501978A1 (da) |
| PL (1) | PL3129018T3 (da) |
| PT (1) | PT3129018T (da) |
| RS (1) | RS59637B1 (da) |
| SG (1) | SG11201608077PA (da) |
| SI (1) | SI3129018T1 (da) |
| UA (1) | UA121208C2 (da) |
| WO (1) | WO2015157697A1 (da) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4137128A1 (en) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same |
| ES2712052T3 (es) * | 2008-10-17 | 2019-05-09 | Cymabay Therapeutics Inc | Métodos para reducir partículas de LDL pequeñas y densas |
| MX2011011538A (es) | 2009-04-29 | 2012-06-13 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| PL3318255T3 (pl) | 2009-06-15 | 2021-09-06 | Amarin Pharmaceuticals Ireland Limited | Kompozycje i sposoby leczenia udaru u pacjenta z jednoczesną terapią statyną |
| RU2758369C2 (ru) | 2009-09-23 | 2021-10-28 | Амарин Фармасьютикалз Айрлэнд Лимитед | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ757815A (en) | 2010-11-29 | 2020-05-29 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US9827219B2 (en) | 2012-01-06 | 2017-11-28 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject |
| IL313596A (en) | 2012-06-29 | 2024-08-01 | Amarin Pharmaceuticals Ie Ltd | Eicosapentaenoic acid and docosapentaenoic acid for use as a drug to reduce the risk of cardiovascular-related death |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) * | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| DK3119384T3 (da) | 2014-03-20 | 2018-12-03 | Cymabay Therapeutics Inc | Behandling af intrahepatiske kolestastiske sygdomme |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| CN106163508A (zh) | 2014-04-11 | 2016-11-23 | 西玛贝医药公司 | Nafld和nash的治疗 |
| AU2015267148B2 (en) | 2014-05-28 | 2021-07-29 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| US20180117013A1 (en) * | 2015-03-26 | 2018-05-03 | T3D Therapeutics, Inc. | Methods of treating liver disease using indane acetic acid derivatives |
| CA2983377C (en) | 2015-04-28 | 2023-08-29 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis |
| US10940125B2 (en) | 2015-09-18 | 2021-03-09 | Duke University | Methods and compositions for the treatment of steatosis-associated disorders |
| WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| GB201614455D0 (en) * | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| CN117229994A (zh) | 2016-11-04 | 2023-12-15 | 儿童医院医学中心 | 肝类器官疾病模型以及其制备和使用方法 |
| US10493363B2 (en) * | 2016-11-09 | 2019-12-03 | Activision Publishing, Inc. | Reality-based video game elements |
| CN110062764B (zh) | 2016-12-05 | 2024-07-02 | 儿童医院医学中心 | 结肠类器官及其制备和使用方法 |
| EP4234536A3 (en) | 2017-05-05 | 2023-10-25 | Hepanova, Inc. | Amino-aryl-benzamide compounds and methods of use thereof |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| EP3681537A1 (en) | 2017-09-13 | 2020-07-22 | Novartis AG | Combinations comprising fxr agonists |
| CN111511372A (zh) * | 2017-10-27 | 2020-08-07 | 株式会社三养社 | 预防或减轻非酒精性脂肪肝疾病的组合物 |
| EP3720431A1 (en) | 2017-12-06 | 2020-10-14 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
| WO2020102351A1 (en) | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Treatment of obesity and its complications |
| AU2019378845A1 (en) | 2018-11-16 | 2021-06-03 | Cymabay Therapeutics, Inc. | Combination treatment of NAFLD and NASH |
| WO2021097027A1 (en) * | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of alcoholic liver disease |
| WO2021097034A1 (en) * | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases |
| CN115811972A (zh) * | 2020-05-13 | 2023-03-17 | 拓臻制药公司 | 肝脏病症的组合治疗 |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| US20240216312A1 (en) * | 2021-05-11 | 2024-07-04 | Genfit | Ppar-agonists for use in the treatment of liver failure |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| AU5359496A (en) | 1995-03-06 | 1996-09-23 | Isis Pharmaceuticals, Inc. | Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| DK0882061T3 (da) | 1996-02-14 | 2004-09-27 | Isis Pharmaceuticals Inc | Sukkermodificerede gapped oligonukleotider |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| ES2328581T3 (es) | 2003-09-19 | 2009-11-16 | Janssen Pharmaceutica Nv | Acidos 4-((fhenoxialquil)tio)-fenoxiaceticos y analogos. |
| NZ549721A (en) | 2004-03-05 | 2010-08-27 | Univ Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| ES2712052T3 (es) | 2008-10-17 | 2019-05-09 | Cymabay Therapeutics Inc | Métodos para reducir partículas de LDL pequeñas y densas |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| EA201691039A1 (ru) | 2013-11-20 | 2016-11-30 | Саймабэй Терапьютикс, Инк. | Лечение гомозиготной семейной гиперхолестеринемии |
| DK3119384T3 (da) | 2014-03-20 | 2018-12-03 | Cymabay Therapeutics Inc | Behandling af intrahepatiske kolestastiske sygdomme |
| CN106163508A (zh) * | 2014-04-11 | 2016-11-23 | 西玛贝医药公司 | Nafld和nash的治疗 |
| JP2017519028A (ja) | 2014-06-26 | 2017-07-13 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 重度の高トリグリセリド血症の処置 |
-
2015
- 2015-04-10 CN CN201580018550.9A patent/CN106163508A/zh active Pending
- 2015-04-10 WO PCT/US2015/025416 patent/WO2015157697A1/en active Application Filing
- 2015-04-10 BR BR112016023269A patent/BR112016023269A8/pt not_active Application Discontinuation
- 2015-04-10 LT LTEP15728222.9T patent/LT3129018T/lt unknown
- 2015-04-10 NZ NZ72474015A patent/NZ724740A/en unknown
- 2015-04-10 SG SG11201608077PA patent/SG11201608077PA/en unknown
- 2015-04-10 JP JP2016561799A patent/JP6865038B2/ja active Active
- 2015-04-10 DK DK15728222.9T patent/DK3129018T3/da active
- 2015-04-10 KR KR1020167031356A patent/KR102374499B1/ko active IP Right Grant
- 2015-04-10 PL PL15728222T patent/PL3129018T3/pl unknown
- 2015-04-10 AU AU2015243239A patent/AU2015243239B2/en active Active
- 2015-04-10 CA CA2944139A patent/CA2944139C/en active Active
- 2015-04-10 EA EA201692050A patent/EA036704B1/ru unknown
- 2015-04-10 UA UAA201609927A patent/UA121208C2/uk unknown
- 2015-04-10 SI SI201531047T patent/SI3129018T1/sl unknown
- 2015-04-10 US US14/684,100 patent/US9381181B2/en active Active
- 2015-04-10 RS RS20191583A patent/RS59637B1/sr unknown
- 2015-04-10 PT PT157282229T patent/PT3129018T/pt unknown
- 2015-04-10 MX MX2016013375A patent/MX369921B/es active IP Right Grant
- 2015-04-10 ES ES15728222T patent/ES2764467T3/es active Active
- 2015-04-10 EP EP15728222.9A patent/EP3129018B1/en active Active
-
2016
- 2016-06-02 US US15/171,910 patent/US9616039B2/en active Active
- 2016-10-04 CL CL2016002517A patent/CL2016002517A1/es unknown
- 2016-10-05 PH PH12016501978A patent/PH12016501978A1/en unknown
- 2016-10-05 IL IL248193A patent/IL248193B/en active IP Right Grant
-
2017
- 2017-03-02 US US15/447,895 patent/US9962346B2/en active Active
-
2018
- 2018-04-03 US US15/943,936 patent/US10188620B2/en active Active
- 2018-12-17 US US16/222,379 patent/US10342770B2/en active Active
-
2019
- 2019-05-23 US US16/420,465 patent/US10722483B2/en active Active
- 2019-12-20 HR HRP20192299TT patent/HRP20192299T1/hr unknown
- 2019-12-20 CY CY20191101347T patent/CY1122602T1/el unknown
-
2020
- 2020-06-19 US US16/906,296 patent/US11179359B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3129018T3 (da) | Behandling af NAFLD og NASH | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| DK3155024T3 (da) | Opholdsstrukturer og relaterede fremgangsmåder | |
| DK2949365T3 (da) | Gåtræningsapparat og gåtræningsfremgangsmåde deraf | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3018183T3 (da) | Halogenolefinbaseret sammensætning og anvendelse deraf | |
| DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
| DK2964255T3 (da) | Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
| DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3237621T3 (da) | Varianter af human alpha-galactosidase | |
| DK3265126T3 (da) | Kombinationsformulering af tesofensin og metoprolol | |
| DK3191103T3 (da) | Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner | |
| DK3183201T3 (da) | Spilsamling og fremgangsmåde til anvendelse | |
| DK3194583T3 (da) | Ikke-fucosyleret protein og fremgangsmåder dermed |